Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CLC001
MIFTS: 51

Calciphylaxis

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Metabolic diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Calciphylaxis

About this section

MalaCards integrated aliases for Calciphylaxis:

Name: Calciphylaxis 12 74 52 58 43 15 71
Idiopathic Calciphylaxis 52

Characteristics:

Orphanet epidemiological data:

58
calciphylaxis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
Anatomical: Cardiovascular diseases Bone diseases Skin diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare circulatory system diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:4734
MeSH 43 D002115
NCIt 49 C84607
ICD10 via Orphanet 33 E83.5
UMLS via Orphanet 72 C0006666
Orphanet 58 ORPHA280062
UMLS 71 C0006666
Sources

Summaries for Calciphylaxis

About this section
NIH Rare Diseases : 52 Calciphylaxis is a disease in which blood vessels (veins and arteries) become blocked by a build-up of calcium in the walls of the vessels, preventing blood from flowing to the skin or internal organs . The lack of blood flow (ischemia ) damages healthy tissue and causes it to die (necrosis ). The most obvious and frequent symptom of calciphylaxis is damage to the skin, as ulcers can develop and become infected easily. Calciphylaxis can also affect fat tissue, internal organs, and skeletal muscle , causing infections, pain, and organ failure. These symptoms are often irreversible, and many individuals with calciphylaxis may not survive more than a few months after they are diagnosed due to infection that spreads throughout the body (sepsis ), or organ failure. The exact cause of calciphylaxis is unknown. Treatments may include medications to reduce pain, antibiotics to treat infections, and various approaches to preventing the development or worsening of this condition.

MalaCards based summary : Calciphylaxis, also known as idiopathic calciphylaxis, is related to end stage renal failure and fournier gangrene. An important gene associated with Calciphylaxis is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Ca, cAMP and Lipid Signaling and Endochondral Ossification. The drugs Capsaicin and Phylloquinone have been mentioned in the context of this disorder. Affiliated tissues include kidney, skin and bone, and related phenotypes are skin ulcer and gangrene

Wikipedia : 74 Calciphylaxis, also known as calcific uremic arteriolopathy (CUA) or "Grey Scale", is a rare painful... more...

Sources

Related Diseases for Calciphylaxis

About this section

Diseases related to Calciphylaxis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 366)
# Related Disease Score Top Affiliating Genes
1 end stage renal failure 31.1 PTH FN1 EPO ALB
2 fournier gangrene 30.6 CD40LG ALB
3 hyperparathyroidism 30.5 VDR PTH FGF23 EPO CASR ALB
4 nephrogenic systemic fibrosis 30.5 SPP1 EPO
5 arteriolosclerosis 30.4 CD79A ALB
6 polyneuropathy 30.4 EPO CD40LG ALB
7 secondary hyperparathyroidism 30.3 VDR PTH FGF23 EPO CASR ALB
8 parathyroid adenoma 30.3 VDR PTH CASR
9 metabolic acidosis 30.2 PTH FGF23 ALB
10 vitamin k deficiency bleeding 30.1 PTH MGP
11 osteitis fibrosa 30.1 PTH FGF23 CASR
12 hypersensitivity vasculitis 30.0 CD40LG ALB
13 cryofibrinogenemia 29.9 FN1 CD79A CD40LG
14 plasma cell neoplasm 29.8 CD79A CD40LG ALB
15 iga glomerulonephritis 29.8 CD79A CD40LG ALB
16 hypoparathyroidism 29.7 VDR PTH FGF23 CASR
17 congestive heart failure 29.6 FN1 EPO ALB
18 cryoglobulinemia 29.6 FN1 CD79A CD40LG
19 skin disease 29.5 VDR CD79A CD40LG ALB
20 acquired immunodeficiency syndrome 29.4 EPO CD79A CD40LG ALB
21 renal osteodystrophy 29.4 VDR PTH FGF23 EPO CASR
22 connective tissue disease 29.4 SPP1 PTH FN1 CD40LG ALB
23 primary hyperparathyroidism 29.2 VDR PTH FGF23 CASR ALB AHSG
24 rickets 29.2 VDR SPP1 PTH FGF23 CASR ALB
25 hypocalcemia, autosomal dominant 1 29.2 VDR PTH FGF23 CASR ALB
26 autoimmune disease 29.2 VDR SPP1 CD79A CD40LG
27 nephrocalcinosis 29.2 SPP1 PTH FGF23 CASR ALB
28 thrombocytopenia 29.2 EPO CD79A CD40LG ALB
29 hypophosphatemia 29.1 VDR SPP1 PTH FGF23 ALB
30 bone disease 29.1 VDR SPP1 PTH FGF23 EPO CASR
31 glomerulonephritis 29.0 SPP1 FN1 CD79A CD40LG ALB
32 hyperphosphatemia 29.0 VDR SPP1 PTH MGP FGF23 CASR
33 calcinosis 28.9 SPP1 PTH MGP FGF23 AHSG
34 bone resorption disease 28.6 VDR SPP1 PTH FGF23 CASR ALB
35 vascular disease 28.4 SPP1 PTH MGP FN1 EPO CD40LG
36 myeloma, multiple 28.3 SPP1 PTH FN1 EPO CD79A CD40LG
37 arterial calcification of infancy 28.1 SPP1 NT5E MGP FGF23 AHSG
38 chronic kidney disease 27.9 VDR SPP1 PTH MGP FGF23 EPO
39 kidney disease 27.5 VDR SPP1 PTH MGP FGF23 EPO
40 uremia 27.5 VDR SPP1 PTH MGP EPO CASR
41 diabetes mellitus 27.4 VDR SPP1 PTH EPO CD40LG CASR
42 nephrolithiasis, calcium oxalate 27.2 VDR SPP1 PTH MGP FGF23 CASR
43 mineral metabolism disease 26.9 VDR SPP1 PTH MGP FGF23 CASR
44 osteoporosis 26.5 VDR SPP1 PTH MGP FGF23 CD40LG
45 visceral calciphylaxis 12.3
46 calciphylaxis cutis 12.3
47 arterial calcification, generalized, of infancy, 1 10.7
48 vasculitis 10.5
49 polycystic kidney disease 4 10.5 FGF23 ALB
50 hypertensive encephalopathy 10.4 EPO ALB

Graphical network of the top 20 diseases related to Calciphylaxis:



Diseases related to Calciphylaxis
Sources

Symptoms & Phenotypes for Calciphylaxis

About this section

Human phenotypes related to Calciphylaxis:

58 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 skin ulcer 58 31 hallmark (90%) Very frequent (99-80%) HP:0200042
2 gangrene 58 31 hallmark (90%) Very frequent (99-80%) HP:0100758
3 cellulitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100658
4 sepsis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100806
5 cutis marmorata 58 31 hallmark (90%) Very frequent (99-80%) HP:0000965
6 hyperphosphatemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002905
7 stage 5 chronic kidney disease 58 31 hallmark (90%) Very frequent (99-80%) HP:0003774
8 secondary hyperparathyroidism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000867
9 abnormality of skin physiology 58 31 hallmark (90%) Very frequent (99-80%) HP:0011122
10 arterial calcification 58 31 hallmark (90%) Very frequent (99-80%) HP:0003207
11 ectopic ossification 58 31 hallmark (90%) Very frequent (99-80%) HP:0011986
12 abnormality of metabolism/homeostasis 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Calciphylaxis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 ALB CD40LG EPO FGF23 FN1 MGP
2 homeostasis/metabolism MP:0005376 10.21 AHSG ALB CASR CD40LG CD79A EPO
3 cellular MP:0005384 10.19 ALB CASR CD40LG CD79A EPO FN1
4 hematopoietic system MP:0005397 10.16 CASR CD40LG CD79A EPO FGF23 FN1
5 growth/size/body region MP:0005378 10.13 AHSG CASR FGF23 FN1 MGP NT5E
6 immune system MP:0005387 10.1 ALB CASR CD40LG CD79A EPO FGF23
7 mortality/aging MP:0010768 10 ALB CASR CD40LG CD79A EPO FGF23
8 integument MP:0010771 9.97 CASR CD40LG EPO FGF23 FN1 NT5E
9 limbs/digits/tail MP:0005371 9.8 AHSG EPO FGF23 FN1 PTH VDR
10 muscle MP:0005369 9.76 AHSG ALB CASR EPO FN1 MGP
11 renal/urinary system MP:0005367 9.61 ALB CASR CD40LG CD79A FGF23 MGP
12 skeleton MP:0005390 9.32 AHSG CASR CD40LG EPO FGF23 FN1
Sources

Drugs & Therapeutics for Calciphylaxis

About this section

Drugs for Calciphylaxis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capsaicin Approved Phase 4 404-86-4 1548943
2
Phylloquinone Approved, Investigational Phase 4 84-80-0
3
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
4 Menaquinone Investigational Phase 4 1182-68-9
5 Dermatologic Agents Phase 4
6 Antipruritics Phase 4
7 Trace Elements Phase 4
8 Micronutrients Phase 4
9 Nutrients Phase 4
10 Hemostatics Phase 4
11 naphthoquinone Phase 4
12 Vitamin K Phase 4
13 Antifibrinolytic Agents Phase 4
14 Vitamins Phase 4
15 Coagulants Phase 4
16 Vitamin K 2 Phase 4
17 Vitamin MK 7 Phase 4
18 Vitamin K 1 Phase 3
19 Pharmaceutical Solutions Phase 2
20
Warfarin Approved 81-81-2 6691 54678486
21
Cisplatin Approved 15663-27-1 84093 441203 2767
22
carbamide peroxide Approved 124-43-6
23
Calcium Approved, Nutraceutical 7440-70-2 271
24 Calcium, Dietary
25 Anesthetics

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
2 Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? Completed NCT02876354 Phase 4 Menaquinone
3 A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial Recruiting NCT03150420 Phase 3 Sodium Thiosulfate;Placebo-Normal Saline
4 Vitamin K1 to Slow Progression of Vascular Calcification in Hemodialysis Patients Active, not recruiting NCT01742273 Phase 3 Vitamin K1
5 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis Not yet recruiting NCT04195906 Phase 3 Experimental: SNF472;Placebo Comparator: Placebo;Experimatenl SNF472 (Open-label)
6 Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy Followed by a Single Armed Extension Phase to Prospectively Observe Lesion Progression in the Presence of Sodium Thiosulfate Treatment Terminated NCT02527213 Phase 3 Sodium thiosulfate;Placebo
7 Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients Completed NCT02790073 Phase 2 SNF472
8 Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff Completed NCT02538939 Phase 2 Sodium thiosulfate
9 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
10 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC) Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo
11 A Randomized, Open Label, Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis Withdrawn NCT01453634 Phase 2 Lunacalcipol 180;Lunicalcipol 270
12 Evaluation of Efficacy of Lanthanum Carbonate (Fosrenol) in Patients With Calciphylaxis Completed NCT01289626 Phase 1 lanthanum carbonate;Lanthanum for calciphylaxis
13 National Follow-up of Dialysis Patients With Sodium Thiosufate-treated Calciphylaxis Under Temporary Use Authorization Unknown status NCT03146793 Sodium Thiosulfate
14 Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort Unknown status NCT02854046
15 Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU): A Comparison of Martorell HYTILU, Calciphylaxis and Venous Ulcer (Control) Unknown status NCT01578382
16 Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy Completed NCT02278692
17 Partners Calciphylaxis Biobank and Patient Registry Recruiting NCT03032835
18 European Calciphylaxis Registry Network Recruiting NCT02635373
19 Impact of Parathyroidectomy on Vascular Calcification and Clinical Outcome in Hemodialysis Patients Recruiting NCT03724188
20 Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate Terminated NCT03319914
21 A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy Terminated NCT01369641 Sodium Thiosulfate (STS);Cisplatin
22 Modulation of Gut Microbiota in End-stage Renal Disease: A Pilot Study Withdrawn NCT02568891

Search NIH Clinical Center for Calciphylaxis

Cochrane evidence based reviews: calciphylaxis

Sources

Genetic Tests for Calciphylaxis

About this section
Sources

Anatomical Context for Calciphylaxis

About this section

MalaCards organs/tissues related to Calciphylaxis:

40
Kidney, Skin, Bone, Breast, Liver, Skeletal Muscle, Lung
Sources

Publications for Calciphylaxis

About this section

Articles related to Calciphylaxis:

(show top 50) (show all 1222)
# Title Authors PMID Year
1
Penile calciphylaxis: a conservative approach. 61
31530167 2020
2
Differential diagnosis of calciphylaxis in chronic dialysis patients. 61
32008200 2020
3
Diffuse dermal angiomatosis associated with calciphylaxis: A 5-year retrospective institutional review. 61
31589777 2020
4
The first case of coexistence of calciphylaxis and nephrogenic systemic fibrosis with different localizations in a hemodialysis patient. 61
31182286 2020
5
Common and critical inflammatory dermatoses every pathologist should know. 61
31676787 2020
6
[AT THE BOTTOM OF THE ULCER - THE IMPORTANCE OF A BIOPSY IN DIAGNOSING HARD TO TREAT ULCERS]. 61
31930802 2020
7
On the role of skin biopsy in the diagnosis of calcific uremic arteriolopathy: a case-based discussion. 61
31792896 2019
8
A persistent penile ulcer in end stage renal disease: It is not always calciphylaxis. 61
31050098 2019
9
Multidisciplinary management of calciphylaxis: a series of 5 patients at a single facility. 61
31849003 2019
10
Penile gangrene due to calciphylaxis: a multidisciplinary approach to a complex clinical challenge. 61
31811092 2019
11
Hybrid image (SPECT/CT) in the early diagnosis of a patient with calciphylaxis. 61
31892485 2019
12
The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. 61
31855262 2019
13
Calciphylaxis: Challenges in the diagnosis and management. 61
31879659 2019
14
Diagnoses of hospitalized patients with skin abnormalities prompting biopsy by consulting dermatologists: A 3-year review from a tertiary care center. 61
31845375 2019
15
Calciphylaxis: A Deceiving Cellulitis. 61
32025437 2019
16
Calciphylaxis in a kidney transplant patient. 61
30314631 2019
17
Calciphylaxis: when a bird is not a duck. 61
31757402 2019
18
Calciphylaxis: Approach to Diagnosis and Management. 61
31831126 2019
19
A Helpful Clue to Calciphylaxis: Subcutaneous Pseudoxanthoma Elasticum-like Changes. 61
31789837 2019
20
Warfarin in nonvalvular atrial fibrillation-Time for a change? 61
31209952 2019
21
Refractory secondary hyperparathyroidism in waiting list for parathyroidectomy: who we should operate first in a quaternary hospital in Brazil regarding survival. 61
30942649 2019
22
Adult T-type lymphoblastic lymphoma presenting as hypercalcemic crisis and aplastic anemia: a case report. 61
31594542 2019
23
Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. 61
31401795 2019
24
Hemodialysis coupled with rheopheresis in calciphylaxis: A winning combination. 61
31322751 2019
25
Rheopheresis: A new therapeutic approach in severe calciphylaxis. 61
31576630 2019
26
Calciphylaxis: a conundrum for patients and nephrologists? 61
31471817 2019
27
Calciphylaxis in a renal transplant patient. 61
31650980 2019
28
Calciphylaxis and its diagnosis: A review. 61
31681640 2019
29
Revisiting therapeutic options for calciphylaxis. 61
31169527 2019
30
Calciphylaxis: Continues to surprise. 61
31486258 2019
31
Hypercalcemia associated with sodium thiosulfate treatment in a patient with calciphylaxis. 61
31111826 2019
32
Multifaceted approach to a rare clinical case of calciphylaxis in a renal transplant recipient. 61
31580546 2019
33
The color of skin: purple diseases of the skin, nails, and mucosa. 61
31896408 2019
34
Clinicopathologic Features and Calcium Deposition Patterns in Calciphylaxis: Comparison With Gangrene, Peripheral Artery Disease, Chronic Stasis, and Thrombotic Vasculopathy. 61
31192861 2019
35
Grover's Disease in a Kidney Transplant Recipient. 61
31542066 2019
36
Effects of parathyroidectomy on tumoral calcinosis in uremic patients with secondary hyperparathyroidism. 61
31510980 2019
37
Penile calciphyilaxis treated with daily Tadalafil: Case report. 61
31372344 2019
38
Calciphylaxis in a dialysis patient treated by intralesional and systemic sodium thiosulphate on top of multifactorial intervention. 61
31384447 2019
39
Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019. 61
31165356 2019
40
The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review. 61
30666627 2019
41
Calciphylaxis due to metastatic well-differentiated neuroendocrine carcinoma. 61
31471365 2019
42
Parathyroidectomy as a Cure for Calciphylaxis in a Non-Dialysis Chronic Kidney Disease Patient? 61
31395848 2019
43
Too Young to Undergo Temporal Artery Biopsy? Calciphylaxis-Related Anterior Ischemic Optic Neuropathy. 61
31528191 2019
44
Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. 61
30785787 2019
45
Successful Treatment of Single Infected Calciphylaxis Lesion With Intralesional Injection of Sodium Thiosulfate at High Concentration. 61
31483755 2019
46
Breakthrough invasive Trichosporon asahii infection in an uremic patient with systemic calciphylaxis complicating necrotizing fasciitis during echinocandin therapy for C. tropicalis. 61
31023578 2019
47
Resolution of acenocoumarol-associated calciphylaxis with drug withdrawal. 61
30790279 2019
48
[The nightmare of calciphylaxis]. 61
31344746 2019
49
Do I Have Calciphylaxis? 61
31116385 2019
50
Localization, Morphologic Features, and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy. 61
31116362 2019
Sources

Variations for Calciphylaxis

About this section
Sources

Expression for Calciphylaxis

About this section
Search GEO for disease gene expression data for Calciphylaxis.
Sources

Pathways for Calciphylaxis

About this section

Pathways related to Calciphylaxis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Ca, cAMP and Lipid Signaling 4
11.68 VDR CASR ALB
2
Endochondral Ossification 1
11.25 SPP1 PTH MGP
3
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.99 VDR SPP1 PTH
4
Parathyroid hormone synthesis, secretion and action 36
10.95 VDR PTH FGF23 CASR
5
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
10.72 VDR SPP1 PTH
6
Osteoblast Signaling 1
10.51 PTH FGF23
7
Vitamin D Metabolism 1
10.32 VDR PTH
Sources

GO Terms for Calciphylaxis

About this section

Cellular components related to Calciphylaxis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 SPP1 PTH FN1 FGF23 EPO CD40LG
2 extracellular region GO:0005576 9.61 SPP1 PTH MGP FN1 FGF23 EPO
3 blood microparticle GO:0072562 9.5 FN1 ALB AHSG
4 platelet alpha granule lumen GO:0031093 9.43 FN1 ALB AHSG
5 endoplasmic reticulum lumen GO:0005788 9.02 SPP1 FN1 FGF23 ALB AHSG

Biological processes related to Calciphylaxis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 skeletal system development GO:0001501 9.72 VDR PTH AHSG
2 platelet degranulation GO:0002576 9.69 FN1 ALB AHSG
3 cellular calcium ion homeostasis GO:0006874 9.63 VDR PTH CASR
4 ossification GO:0001503 9.61 MGP CASR AHSG
5 decidualization GO:0046697 9.56 VDR SPP1
6 post-translational protein modification GO:0043687 9.55 SPP1 FN1 FGF23 ALB AHSG
7 response to vitamin D GO:0033280 9.54 SPP1 PTH
8 negative regulation of bone mineralization GO:0030502 9.52 FGF23 AHSG
9 cellular response to vitamin D GO:0071305 9.49 FGF23 CASR
10 vitamin D metabolic process GO:0042359 9.48 VDR FGF23
11 acute-phase response GO:0006953 9.43 FN1 EPO AHSG
12 response to fibroblast growth factor GO:0071774 9.4 PTH CASR
13 phosphate ion homeostasis GO:0055062 9.37 PTH FGF23
14 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.32 VDR FGF23
15 regulation of bone mineralization GO:0030500 9.13 MGP FGF23 AHSG
16 cellular protein metabolic process GO:0044267 9.02 SPP1 FN1 FGF23 ALB AHSG

Molecular functions related to Calciphylaxis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 8.92 SPP1 FN1 CD40LG CASR
Sources

Sources for Calciphylaxis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....